Insider Selling: Medline (NASDAQ:MDLN) Major Shareholder Sells $9,609,548.02 in Stock

Key Points

• Major shareholder Private Ltd Gic sold 271,994 Medline shares for approximately $9.6 million, reducing its ownership by 1.08%; it also sold nearly 2 million shares for about $70.4 million the previous day.
• Medline reported quarterly EPS of $0.50, beating the $0.32 consensus estimate, with revenue of roughly $7.68 billion. The company raised its 2026 organic-sales growth outlook to 9%–10% but lowered adjusted EBITDA guidance to $3.3 billion–$3.4 billion, signaling potential margin pressure.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $48.50 price target, although several firms recently cut their targets. Medline also faces potential legal and regulatory risks following law-firm investigations tied to an FDA warning letter.

Medline (NASDAQ:MDLN - Get Free Report) major shareholder Private Ltd Gic sold 271,994 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $35.33, for a total transaction of $9,609,548.02. Following the completion of the sale, the insider owned 24,992,766 shares in the company, valued at approximately $882,994,422.78. This trade represents a 1.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The stock was sold at an average price of $35.60, for a total value of $70,367,600.80.

Medline Trading Up 2.1%

MDLN traded up $0.72 on Friday, hitting $35.23. The company had a trading volume of 8,293,636 shares, compared to its average volume of 7,380,132. The business's fifty day simple moving average is $38.24 and its 200 day simple moving average is $41.77. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65. Medline has a 12-month low of $32.81 and a 12-month high of $50.88. The company has a market cap of $46.28 billion and a PE ratio of 110.09.

Medline (NASDAQ:MDLN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion during the quarter. Equities research analysts expect that Medline will post 1.49 EPS for the current year.

Institutional Investors Weigh In On Medline

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new stake in shares of Medline in the 2nd quarter worth $40,430,000. E. Ohman J or Asset Management AB purchased a new position in shares of Medline during the second quarter valued at $508,000. GAMMA Investing LLC raised its holdings in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company's stock valued at $25,000 after acquiring an additional 254 shares in the last quarter. Parallel Advisors LLC lifted its stake in Medline by 1,073.3% in the first quarter. Parallel Advisors LLC now owns 5,280 shares of the company's stock worth $235,000 after acquiring an additional 4,830 shares during the period. Finally, CTC Alternative Strategies Ltd. purchased a new position in Medline during the 1st quarter valued at about $1,048,000.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, exceeding the $0.32 analyst consensus, while revenue reached $7.69 billion. The company also raised its 2026 organic-sales growth forecast to 9%–10%, signaling continued demand for its medical products. Medline Q2 Earnings Snapshot Medline Raises 2026 Organic Sales Outlook
• Positive Sentiment: BTIG reiterated a Buy rating and $55 price target, citing robust growth and viewing current headwinds as transitory. At that target, the shares would have substantial potential upside from recent trading levels. BTIG Medline Rating
• Neutral Sentiment: Truist lowered its price target from $56 to $47, and Stifel reduced its target from $50 to $45, but both firms maintained Buy ratings. The target cuts reflect increased caution, while the continued recommendations indicate analysts still see meaningful long-term upside. Truist Price Target Update Stifel Price Target Update
• Negative Sentiment: Medline lowered its 2026 adjusted EBITDA forecast to $3.3 billion–$3.4 billion despite the sales outlook increase. The weaker profit guidance has weighed on the stock because it suggests margin pressure or higher costs and offsets the quarterly earnings beat. Medline Falls After EBITDA Outlook Cut
• Negative Sentiment: Several law firms, including Kaplan Fox and Kessler Topaz, announced investigations into potential securities-law violations involving Medline. The actions follow an FDA warning letter reportedly identifying significant violations. These announcements create legal, regulatory and reputational risks, although the investigations do not establish wrongdoing. Kaplan Fox Medline Investigation Kessler Topaz Medline Investigation

Wall Street Analyst Weigh In

Several analysts have issued reports on MDLN shares. Deutsche Bank Aktiengesellschaft set a $37.00 price objective on shares of Medline in a research note on Thursday. Evercore set a $39.00 price target on Medline in a report on Thursday. BNP Paribas Exane dropped their price objective on Medline from $49.00 to $40.00 and set a "neutral" rating for the company in a report on Thursday, May 14th. Tigress Financial upped their price objective on Medline from $60.00 to $62.00 and gave the company a "buy" rating in a research report on Wednesday, May 13th. Finally, BTIG Research reiterated a "buy" rating and issued a $55.00 target price on shares of Medline in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.

Medline Company Profile

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source